BRPI0807749B8 - composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos - Google Patents
composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicosInfo
- Publication number
- BRPI0807749B8 BRPI0807749B8 BRPI0807749A BRPI0807749A BRPI0807749B8 BR PI0807749 B8 BRPI0807749 B8 BR PI0807749B8 BR PI0807749 A BRPI0807749 A BR PI0807749A BR PI0807749 A BRPI0807749 A BR PI0807749A BR PI0807749 B8 BRPI0807749 B8 BR PI0807749B8
- Authority
- BR
- Brazil
- Prior art keywords
- prevention
- treatment
- compound
- acute
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPOSTO,COMPOSIÇÃO FARMACÊUTICA, E MÉTODO PARA A PREVENÇÃO, TRATAMENTO OU MELHORA, E, MÉTODO PARA A PREVENÇÃO, TRATAMENTO OU MELHORA DE DOENÇAS OU CONDIÇÕES DÉRMICAS, OU DISTÚRBIOS DE FERIDA CUTÂNEA AGUDOS OU CRÔNICAS. A presente invenção refere-se a um composto de acordo com a formula I, em que X, A, G, E, R2, R3 são como aqui mostrados; e sais farmaceuticamente aceitáveis dos mesmos, hidratos, N-óxidos e solvatos dos mesmos. A invenção refere-se ainda aos referidos compostos para o uso em terapia, a composições farmacêuticas que compreendem os referidos compostos, e a métodos para o tratamento de doenças, por exemplo, doenças dérmicas, com os referidos compostos, e ao uso dos referidos compostos na manufatura de medicamentos. .
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90384907P | 2007-02-28 | 2007-02-28 | |
| US60/903849 | 2007-02-28 | ||
| US94684907P | 2007-06-28 | 2007-06-28 | |
| US60/946849 | 2007-06-28 | ||
| PCT/DK2008/000080 WO2008104175A2 (en) | 2007-02-28 | 2008-02-26 | Novel phosphodiesterase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0807749A2 BRPI0807749A2 (pt) | 2014-06-17 |
| BRPI0807749B1 BRPI0807749B1 (pt) | 2021-01-05 |
| BRPI0807749B8 true BRPI0807749B8 (pt) | 2022-09-06 |
Family
ID=39415336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0807749A BRPI0807749B8 (pt) | 2007-02-28 | 2008-02-26 | composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8338431B2 (pt) |
| EP (1) | EP2114951B9 (pt) |
| JP (1) | JP5501770B2 (pt) |
| KR (1) | KR101571654B1 (pt) |
| AU (1) | AU2008221121B2 (pt) |
| BR (1) | BRPI0807749B8 (pt) |
| CA (1) | CA2676933C (pt) |
| CY (1) | CY1115227T1 (pt) |
| DK (1) | DK2114951T3 (pt) |
| ES (1) | ES2478670T3 (pt) |
| HR (1) | HRP20140585T1 (pt) |
| IL (1) | IL200153A (pt) |
| MX (1) | MX2009009238A (pt) |
| MY (1) | MY150075A (pt) |
| NZ (1) | NZ578804A (pt) |
| PL (1) | PL2114951T3 (pt) |
| PT (1) | PT2114951E (pt) |
| RS (1) | RS53407B (pt) |
| RU (1) | RU2495043C2 (pt) |
| SI (1) | SI2114951T1 (pt) |
| WO (1) | WO2008104175A2 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012007225A (es) | 2009-12-22 | 2012-07-30 | Leo Pharma As | Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d. |
| MX2012007234A (es) | 2009-12-22 | 2012-07-30 | Leo Pharma As | Nanocristales de monohidrato de calciprotiol. |
| RU2560677C2 (ru) | 2009-12-22 | 2015-08-20 | Лео Фарма А/С | Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ |
| JP6174997B2 (ja) * | 2010-06-24 | 2017-08-02 | レオ ファーマ アクティーゼルスカブ | ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物 |
| WO2013122855A1 (en) * | 2012-02-14 | 2013-08-22 | University Of Rochester | Methods of increasing lymphatic transport |
| KR20150022789A (ko) * | 2012-06-04 | 2015-03-04 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체 |
| WO2014083099A1 (en) * | 2012-11-30 | 2014-06-05 | Leo Pharma A/S | A method of inhibiting the expression of il-22 in activated t-cells |
| JP6785666B2 (ja) | 2014-06-23 | 2020-11-18 | レオ ファーマ アクティーゼルスカブ | １，３−ベンゾジオキソール複素環化合物の調製方法 |
| US10160750B2 (en) | 2015-06-19 | 2018-12-25 | Bristol-Myers Squibb Company | Diamide macrocycles as factor XIa inhibitors |
| DK3390407T3 (da) * | 2015-12-18 | 2023-11-06 | Union Therapeutics As | Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser |
| CN110088108B (zh) * | 2016-12-12 | 2024-06-14 | 联合疗法公司 | 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途 |
| US11065257B2 (en) * | 2016-12-12 | 2021-07-20 | Leo Pharma A/S | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors |
| ES2874632T3 (es) * | 2016-12-12 | 2021-11-05 | Union Therapeutics As | Pirazoloazepin-8-onas sustituidas y su uso como inhibidores de la fosfodiesterasa |
| AU2018286964B2 (en) | 2017-06-20 | 2022-04-14 | UNION therapeutics A/S | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds |
| TW201919682A (zh) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Ｎｒｆ２路徑的新穎化合物 |
| WO2019115776A1 (en) | 2017-12-15 | 2019-06-20 | Leo Pharma A/S | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors |
| GB202306662D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Dosage regimen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9507297D0 (en) | 1995-04-07 | 1995-05-31 | Rh Ne Poulenc Rorer Limited | New composition of matter |
| HK1000785A1 (en) | 1995-05-19 | 2006-06-30 | Kyowa Hakko Kogyo Co., Ltd | Oxygen-containing heterocyclic compounds |
| US6514996B2 (en) * | 1995-05-19 | 2003-02-04 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of benzofuran or benzodioxole |
| HUP0100042A3 (en) * | 1996-05-20 | 2003-01-28 | Darwin Discovery Ltd Cambridge | Benzofuran carboxamides medicaments containing the same and their therapeutic use |
| TR199900429T2 (xx) * | 1996-08-28 | 1999-05-21 | The Procter & Gamble Company | Spirosiklik metaloproteaz inhibit�rleri. |
| AU4967697A (en) * | 1996-11-19 | 1998-06-10 | Kyowa Hakko Kogyo Co. Ltd. | Oxygenic heterocyclic compounds |
| EP1029860B1 (en) * | 1997-10-01 | 2003-04-16 | Kyowa Hakko Kogyo Co., Ltd. | Benzofuran derivatives |
-
2008
- 2008-02-26 PL PL08706922T patent/PL2114951T3/pl unknown
- 2008-02-26 NZ NZ578804A patent/NZ578804A/en not_active IP Right Cessation
- 2008-02-26 HR HRP20140585AT patent/HRP20140585T1/hr unknown
- 2008-02-26 RS RS20140365A patent/RS53407B/sr unknown
- 2008-02-26 BR BRPI0807749A patent/BRPI0807749B8/pt not_active IP Right Cessation
- 2008-02-26 SI SI200831224T patent/SI2114951T1/sl unknown
- 2008-02-26 DK DK08706922.5T patent/DK2114951T3/da active
- 2008-02-26 KR KR1020097018073A patent/KR101571654B1/ko active Active
- 2008-02-26 US US12/528,649 patent/US8338431B2/en active Active
- 2008-02-26 JP JP2009551915A patent/JP5501770B2/ja not_active Expired - Fee Related
- 2008-02-26 RU RU2009135810/04A patent/RU2495043C2/ru active
- 2008-02-26 PT PT87069225T patent/PT2114951E/pt unknown
- 2008-02-26 MY MYPI20093168A patent/MY150075A/en unknown
- 2008-02-26 MX MX2009009238A patent/MX2009009238A/es active IP Right Grant
- 2008-02-26 CA CA2676933A patent/CA2676933C/en active Active
- 2008-02-26 WO PCT/DK2008/000080 patent/WO2008104175A2/en not_active Ceased
- 2008-02-26 ES ES08706922.5T patent/ES2478670T3/es active Active
- 2008-02-26 EP EP08706922.5A patent/EP2114951B9/en active Active
- 2008-02-26 AU AU2008221121A patent/AU2008221121B2/en not_active Ceased
-
2009
- 2009-07-30 IL IL200153A patent/IL200153A/en active IP Right Grant
-
2014
- 2014-06-17 CY CY20141100437T patent/CY1115227T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2478670T3 (es) | 2014-07-22 |
| JP5501770B2 (ja) | 2014-05-28 |
| IL200153A0 (en) | 2010-04-15 |
| US20100099688A1 (en) | 2010-04-22 |
| CY1115227T1 (el) | 2017-01-04 |
| AU2008221121B2 (en) | 2013-10-03 |
| RU2009135810A (ru) | 2011-04-10 |
| PT2114951E (pt) | 2014-07-17 |
| PL2114951T3 (pl) | 2014-10-31 |
| HRP20140585T1 (hr) | 2014-09-12 |
| BRPI0807749B1 (pt) | 2021-01-05 |
| EP2114951B9 (en) | 2015-09-02 |
| HK1138262A1 (en) | 2010-08-20 |
| AU2008221121A1 (en) | 2008-09-04 |
| MY150075A (en) | 2013-11-29 |
| WO2008104175A2 (en) | 2008-09-04 |
| CA2676933A1 (en) | 2008-09-04 |
| SI2114951T1 (sl) | 2014-08-29 |
| RS53407B (sr) | 2014-10-31 |
| RU2495043C2 (ru) | 2013-10-10 |
| JP2010519332A (ja) | 2010-06-03 |
| KR20090126252A (ko) | 2009-12-08 |
| IL200153A (en) | 2016-11-30 |
| CA2676933C (en) | 2015-09-29 |
| NZ578804A (en) | 2012-04-27 |
| MX2009009238A (es) | 2009-09-08 |
| EP2114951A2 (en) | 2009-11-11 |
| DK2114951T3 (da) | 2014-06-23 |
| US8338431B2 (en) | 2012-12-25 |
| WO2008104175A3 (en) | 2009-01-29 |
| KR101571654B1 (ko) | 2015-11-25 |
| EP2114951B1 (en) | 2014-04-09 |
| BRPI0807749A2 (pt) | 2014-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BRPI0714803B8 (pt) | compostos peptidomiméticos de smac, seus usos, e composição farmacêutica | |
| BR112013020620A2 (pt) | análogos de ácido 4-hidroxibutírico | |
| BRPI0514841A (pt) | inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores | |
| BRPI0518846A2 (pt) | composto, composiÇço farmacÊutica, mÉtodos de tratar, ou reduzir o risco de doenÇas ou condiÇÕes em que inibiÇço da enzima mpo É benÉfica e de tratar, ou reduzir o risco de distérbios neuroinflamatàrios, uso de um composto, e, processo para a preparaÇço de um composto | |
| BR112013027241A2 (pt) | "composto inibidor de rock, composição que o compreende e seus usos" | |
| BR112014015845A8 (pt) | derivados de azetidina, composições farmacêuticas e seu uso | |
| BRPI0717367B8 (pt) | di-hidropirazolonas substituídas, seus usos e seu processo de preparação, e medicamento | |
| BR112014007721A2 (pt) | processos para preparar compostos úteis como inibidores de atr quinase | |
| BR112015014458A8 (pt) | compostos derivados de manose, seus intermediários, composição, uso e processos de preparação | |
| BR112012010705A2 (pt) | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio | |
| BRPI0720270B8 (pt) | compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| BR112013029240A2 (pt) | derivados deuterados do ivacaftor | |
| BR112014013661A8 (pt) | derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
| BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
| BR112018067930A2 (pt) | composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto. | |
| BR112014000371A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
| BR112012013854A2 (pt) | derivados de oxazina. | |
| BR112012008889A2 (pt) | compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes | |
| BRPI0720551A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| UY33246A (es) | Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas | |
| MX2009009238A (es) | Nuevos inhibidores de fosfodiesterasa. | |
| BRPI0514133A (pt) | compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25A | Requested transfer of rights approved |
Owner name: UNION THERAPEUTICS A/S (DK) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: LEO PHARMA A/S (DK) Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2671 DE 15/03/2022 POR TER SIDO INDEVIDA. |
|
| B25A | Requested transfer of rights approved |
Owner name: UNION THERAPEUTICS A/S (DK) |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2868 DE 23-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |